
Myelodysplastic syndrome is a group of cancers that prevents hematopoietic stem cells from developing into healthy blood cells. Without enough healthy blood cells, people risk developing dangerous illnesses such as anaemia, frequent infections, and uncontrollable bleeding. Some patients with MDS may develop acute myeloid leukaemia (AML).
Myelodysplastic Syndrome (MDS) should be treated as soon as possible to prevent it from progressing to acute myeloid leukaemia (AML), relieve symptoms such as fatigue and anaemia, and improve general health.
Early intervention enhances the efficacy of chemotherapy and stem cell transplants, improving outcomes. It also helps to reduce life-threatening complications such as infections and bleeding, which improves the prognosis and survival rates.
Therefore, timely treatment is critical for effectively controlling MDS and giving patients a better long-term outlook.
People with myelodysplastic syndromes may not exhibit signs and symptoms at first.
Myelodysplastic syndromes could cause:
The World Health Organization classifies myelodysplastic syndromes into subcategories based on the kind of blood cells involved (red cells, white cells, and platelets).
The myelodysplastic syndrome has several subtypes, including:
Causes
Risk Factors
The following factors can raise your risk of myelodysplastic syndromes:
Complications
Myelodysplastic syndromes can have the following complications:
Chemotherapy: Healthcare practitioners may administer the same chemotherapy used to treat AML. It uses medications to eliminate cancer cells and inhibit tumour growth.
Cost Start From USD 7420 - USD 30000Explore Options
Immunosuppressive therapy: Providers may utilise this medication for some MDS subtypes. Immunosuppressive medication reduces overactive immune systems, reducing the need for transfusions.
Cost Start From USD 7420 - USD 42500Explore Options
Bone Marrow Transplant: A bone marrow transplant, also known as a stem cell transplant, is the only treatment that can cure myelodysplastic disorders.
Cost Start From USD 50000 - USD 80000Explore Options
Rehabilitation for Hepatocellular Carcinoma (HCC) is an essential component of the rehabilitation process and enhances quality of life, particularly following surgery, liver transplantation, or other treatments. Here are some indispensable rehabilitation choices for HCC patients:
MediGence can assist and guide you in selecting the best physician and medical facility for your care.
Treatment for myelodysplastic syndromes may include medications such as:









Istanbul, Turkey
Medicana Camlica Hospital located in Istanbul, Turkey is accredited by JCI. Also listed below are some of the most prominent infrastructural details:

Istanbul, Turkey
Architecture of the Hospital designed as per the comfort of patients-

Istanbul, Turkey
Acibadem Kadikoy Hospital located in Istanbul, Turkey is accredited by JCI. Also listed below are some of the most prominent infrastructural details:
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Here are the reasons for selecting Turkey for Myelodysplastic syndrome (MDS) treatment.
In Turkey, patients with Myelodysplastic Syndromes (MDS) have varying life expectancies based on age, illness risk classification, and health status. The median survival time ranges from a few months to more than a decade. However, survival rates can vary depending on disease severity and individual health. Patients should speak with healthcare specialists to discover their unique prognosis and treatment options.
MDS and leukaemia involve the bone marrow and blood cells, but MDS is a disorder in which the bone marrow generates abnormal cells. In contrast, leukaemia is characterised by the fast, uncontrolled proliferation of defective blood cells. MDS is sometimes thought to be a precursor to leukaemia since it can progress to acute myeloid leukaemia (AML) in some circumstances; however, the two illnesses are separate.
While most cases of MDS are not inherited, specific gene changes can raise the chance of getting the disease. In rare situations, MDS can be inherited as part of a genetic condition, such as Fanconi anaemia. You should speak with a genetic counsellor if you have a family history of blood diseases.
Yes, myelodysplastic syndromes (MDS) are treatable in Turkey. The country has innovative healthcare facilities and professional oncologists who offer treatments like chemotherapy, stem cell transplants, and targeted medications.
Turkey's medical centers use advanced equipment and offer personalised care, enhancing the chances of effective management and better outcomes for MDS patients.
Chemotherapy is often used to treat high-risk MDS and instances that develop to acute myeloid leukemia.
Chemotherapy removes abnormal cells from the bone marrow and restores normal blood cell production.
In Turkey, chemotherapy for MDS is provided in big cancer hospitals, where specialists customise treatment plans.
Many MDS patients can have quite normal lives with the right treatment. However, symptoms such as fatigue, persistent infections, and the need for blood transfusions can have a significant influence on one's life. Patients can usually retain a high quality of life after undergoing therapy such as blood transfusions, medicines, and stem cell transplants.
Turkey is now conducting research and clinical trials to develop novel medications for MDS, such as innovative pharmaceuticals, immunotherapies, and targeted treatments. Some novel medicines aim to increase survival rates and lower the likelihood of MDS becoming leukemia. Patients can discuss these alternatives with their doctor to learn more about new treatments.